Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single dose
ABCL635 significantly improved sleep and patient global impression of change
ABCL635 demonstrated a favorable tolerability profile
AbCellera to host a conference call and live webcast today at 4:30 a....
Subscribe to BIOTECanada’s news feed.
Click on “Follow” and decide if you want to get news from BIOTECanada via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to BIOTECanada comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from BIOTECanada which you are really interested in. Click on the blue “Filter” button below to get started.
Website title: Home - BIOTECanada